FDA AdComm Prep For Gilead’s Sofosbuvir Shows Agency Thinking On HCV Dosing
This article was originally published in The Pink Sheet Daily
FDA staff cites a favorable benefit-risk assessment for sofosbuvir, though evidence is insufficient to support dosing recommendation in patients with HCV genotypes 5 and 6. Dosing duration and use in prior nonresponders and pre-transplant patients will be discussed by Antiviral Drugs Advisory Committee Oct. 25.
You may also be interested in...
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.